Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report.
Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report.
- 2023
Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim.
English
2234-943X
10.3389/fonc.2023.1134151 [doi] PMC10046803 [pmc]
--Automated
MedStar Washington Hospital Center
Hematology & Oncology Fellowship
Internal Medicine Residency
MedStar Georgetown University Hospital/MedStar Washington Hospital Center
Case Reports
Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim.
English
2234-943X
10.3389/fonc.2023.1134151 [doi] PMC10046803 [pmc]
--Automated
MedStar Washington Hospital Center
Hematology & Oncology Fellowship
Internal Medicine Residency
MedStar Georgetown University Hospital/MedStar Washington Hospital Center
Case Reports